Kayne Anderson Rudnick Investment Management LLC Has $333.30 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Kayne Anderson Rudnick Investment Management LLC lessened its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 6.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,805,541 shares of the medical research company’s stock after selling 134,284 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned approximately 3.53% of Charles River Laboratories International worth $333,303,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Virtu Financial LLC acquired a new stake in shares of Charles River Laboratories International in the 3rd quarter valued at $601,000. JPMorgan Chase & Co. raised its stake in Charles River Laboratories International by 21.6% during the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock worth $95,086,000 after acquiring an additional 85,759 shares in the last quarter. Veracity Capital LLC acquired a new stake in shares of Charles River Laboratories International in the 4th quarter valued at approximately $589,000. Lord Abbett & CO. LLC grew its holdings in shares of Charles River Laboratories International by 5.8% during the 3rd quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company’s stock valued at $21,413,000 after purchasing an additional 5,959 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company’s stock worth $330,231,000 after purchasing an additional 47,221 shares in the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Trading Up 1.6 %

Shares of CRL stock opened at $105.89 on Friday. The company has a market cap of $5.20 billion, a P/E ratio of 705.91, a PEG ratio of 4.54 and a beta of 1.45. Charles River Laboratories International, Inc. has a fifty-two week low of $91.86 and a fifty-two week high of $254.15. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a 50 day simple moving average of $151.07 and a two-hundred day simple moving average of $173.87.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.63 million. During the same period last year, the company posted $2.46 earnings per share. The business’s quarterly revenue was down 1.1% on a year-over-year basis. Research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Analyst Upgrades and Downgrades

CRL has been the subject of several research analyst reports. The Goldman Sachs Group downgraded shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Morgan Stanley lowered their price objective on Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 5th. Citigroup upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and lifted their target price for the stock from $155.00 to $175.00 in a research report on Tuesday, March 4th. UBS Group restated a “neutral” rating and issued a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. Finally, JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have issued a hold rating to the company’s stock. According to MarketBeat.com, Charles River Laboratories International currently has a consensus rating of “Hold” and a consensus price target of $182.00.

Insider Activity at Charles River Laboratories International

In other news, COO Birgit Girshick bought 1,514 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were bought at an average cost of $164.63 per share, for a total transaction of $249,249.82. Following the acquisition, the chief operating officer now directly owns 55,058 shares in the company, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO James C. Foster purchased 6,075 shares of the firm’s stock in a transaction on Thursday, February 20th. The shares were acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the purchase, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. This represents a 3.42 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).